Trademark Search in Canada

VISTAGEN

View On IC.GC.CA

REGISTERED

on 4 Apr 2024

Last Applicant/ Owned by

VISTAGEN THERAPEUTICS INC.

343 Allerton AvenueSouth San Francisco CA 94080

Serial Number

2156005 filed on 6^th Aug 2021

Registration Number

TMA1227989 registered on 4^th Apr 2024

Registration expiry Date

6^th Aug 2031

Correspondent Address

GOWLING WLG (CANADA) LLP

550 BURRARD STREETSUITE 2300VANCOUVER

BRITISH COLUMBIA

V6C2B5

VISTAGEN

Trademark usage description

pharmaceuticals, namely medicines for the treatment of mental health disorders; pharmaceutical preparations for the treatment of central nervous syste Read More

Classification Information

Class [005]
Pharmaceuticals, namely medicines for the treatment of mental health disorders; pharmaceutical preparations for the treatment of central nervous system [cns] diseases.

Classification kind code

Mark Details

Serial Number

2156005

Mark Type

Trademark

Legal History

Action Taken	Status
Submitted for opposition 22 on 24^th Mar 2023	Search Recorded
Submitted for opposition 20 on 24^th Mar 2023	Examiner's First Report
Submitted for opposition 223 on 24^th Mar 2023	Total Provisional Refusal
Submitted for opposition 256 on 24^th Oct 2022	Notification of Possible Opposition Sent
Submitted for opposition 48 on 14^th Jan 2022	Agent Changed
Submitted for opposition 257 on 23^rd Dec 2021	Designation Notification - Madrid Protocol
Submitted for opposition 31 on 22^nd Dec 2021	Formalized
Submitted for opposition 1 on 22^nd Dec 2021	Created
Submitted for opposition 228 on 6^th Aug 2021	International Registration
Submitted for opposition 30 on 6^th Aug 2021	Filed

VISTAGEN

Classification Information

Class [005]Pharmaceuticals, namely medicines for the treatment of mental health disorders; pharmaceutical preparations for the treatment of central nervous system [cns] diseases.

Classification kind code

Mark Details

Serial Number

Mark Type

Legal History

Class [005]
Pharmaceuticals, namely medicines for the treatment of mental health disorders; pharmaceutical preparations for the treatment of central nervous system [cns] diseases.